Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Apr 21, 2021 12:24pm
133 Views
Post# 33037514

RE:Bloom Burton

RE:Bloom Burton

Christain is just so much more comfortable with the science, Paul to some extent seems to be dumbing it down for non-science people which is not a bad thing. There's no question cancer is problem free at this point in time and overachieving in some areas, there's no wonder he's gushing.

NASH again solid on the timeline. If Q&As have been exchanged then we must be well into that 30day period prior to the meeting. Sounds like he is anticipating a re-submission of the protocol, getting that in our rear view mirror is key. So progress on the process without a change to the timeline, seems positive. I have to say I thought he got VERY wobbly when it came to the EMA, I'm staying sceptical on that.


SPCEO1 wrote: My main takeaway from the Bloom Burton presentation is that whatever they are seeing with the first patient in the cancer trial is not dimming their enthusiasm for their cancer prospects in the last. Just the opposite apparently, which is something that should make us all breath a sigh of releif. Every day that goes by where there is no bad news is good news. Anytime the CEO cannot find enough superlatives (causing Wino much wincing, no doubt) to describe the cancer program is a very good day for us. 

 

<< Previous
Bullboard Posts
Next >>